<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111043</article-id><article-id pub-id-type="publisher-id">ACM-40012</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_41887002.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  呼吸科非血栓住院患者血浆D-二聚体水平分析
  On Admission Plasma Levels of D-Dimer in Patients with Pulmonary Diseases Free from Thromboembolic Clinical Conditions
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>志强</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>珍慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>崔</surname><given-names>瑷</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，呼吸与危重症医学科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>首都医科大学附属北京朝阳医院——北京呼吸疾病研究所，北京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>293</fpage><lpage>301</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    背景与目的：D-二聚体检测对血栓栓塞性疾病的诊断有明显的帮助作用，敏感性高，但特异性差，很多非血栓性疾病也可见血浆D-二聚体水平升高。本研究通过观察和比较不同的呼吸系统疾病患者血浆D-二聚体水平，进一步评价其在呼吸系统疾病中的诊断价值。方法：本研究纳入自2019年4月至2019年6月青岛大学附属医院全部住院患者，排除其中合并有血栓栓塞性疾病患者及诊断不清者，收集相关临床资料，采用酶联免疫吸附试验(ELISA)检测患者住院当天血浆中D-二聚体的水平，按照出院时确定诊断对患者进行分组，评价D-二聚体在呼吸系统各疾病中检测水平的差异。结果：共纳入365例患者，其中静脉血栓栓塞症(Venous Thromboembolism, VTE)患者26例；其他患者339例，包括慢性阻塞性肺疾病，间质性肺病，支气管扩张，支气管哮喘，社区获得性肺炎，肺癌以及肺结核。VTE组中血浆D-二聚体水平(1800.3 &#177; 1686.8 ng/ml)显著高于非VTE组中血浆D-二聚体水平(1050.3 &#177; 1425.4 ng/ml) (p = 0.001)，但血浆D-二聚体水平在VTE与结核和肺癌无差异。无论是结核、肿瘤，还是社区获得性肺炎，伴有胸腔积液的患者血浆D-二聚体水平比不伴有胸腔积液的患者显著升高。用来鉴别结核性胸腔积液(TPE)和恶性胸腔积液(MPE)的血浆D-二聚体水平曲线下面积为0.796 (95%置信区间：0.571~0.968)。临界值为1720 ng/ml，灵敏度为69.2%，特异性为83.3%。结论：血浆D-二聚体水平升高对于鉴别VTE与其他非血栓性呼吸系统疾病的价值有限，尤其是结核和肿瘤。而血浆D-二聚体水平在TPE明显升高，其水平显著超过MPE，血浆D-二聚体水平可能作为鉴别TPE和MPE的一个辅助指标。
    Background and Objectives: The use of D-dimer testing improved the diagnostics in pulmonary embolism and venous thrombosis (VTE). The aim of the present study was to evaluate and compare the serum D-dimer levels in patients with various lung diseases and determine whether serum D-dimer could be helpful in predicting the etiology of those pulmonary diseases. Patients and Methods: The study group included 365 consecutive patients. There were 26 with acute VTE, 339 with COPD, interstitial lung diseases (ILDs), bronchiectasis, asthma, community-acquired pneumonia (CAP), lung malignancy and tuberculosis (TB). Plasma D-dimer levels were analyzed by using an ELISA-method on the day of admission. Results: Mean plasma D-dimer concentration was 1800.3 &#177; 1686.8 ng/ml in VTE and 1050.3 &#177; 1425.4 ng/ml in the non-VTE group (p = 0.001), especially in lung cancer, CAP, ILDs and TB. There was a significant elevated level of D-dimer in patients with pleural effusion (2085.7 &#177; 1707.4 ng/ml) compared with each diseases without pleural effusion (1041.1 &#177; 1230.8 ng/ml) (p &lt; 0.01). The area under curve when plasma D-dimer was used to differentiate TPE from MPE was 0.796 (95% confidence interval: 0.571~0.968). With a cut-off value of 1720 ng/ml, the sensitivity was 69.2% and the specificity was 83.3%. Conclusions: Plasma D-dimer levels are as higher as VTE in many lung diseases including lung cancer, CAP, ILDs and TB, especially in those diseases with pleural effusion. TPE has extremely elevated plasma D-dimer level and it may serve as a differential diagnostic marker for TPE from MPE. 
  
 
</p></abstract><kwd-group><kwd>D-二聚体，肺结核，肺癌，胸腔积液，诊断, D-Dimer</kwd><kwd> Tuberculosis</kwd><kwd> Lung Cancer</kwd><kwd> Pleural Effusion</kwd><kwd> Diagnosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>背景与目的：D-二聚体检测对血栓栓塞性疾病的诊断有明显的帮助作用，敏感性高，但特异性差，很多非血栓性疾病也可见血浆D-二聚体水平升高。本研究通过观察和比较不同的呼吸系统疾病患者血浆D-二聚体水平，进一步评价其在呼吸系统疾病中的诊断价值。方法：本研究纳入自2019年4月至2019年6月青岛大学附属医院全部住院患者，排除其中合并有血栓栓塞性疾病患者及诊断不清者，收集相关临床资料，采用酶联免疫吸附试验(ELISA)检测患者住院当天血浆中D-二聚体的水平，按照出院时确定诊断对患者进行分组，评价D-二聚体在呼吸系统各疾病中检测水平的差异。结果：共纳入365例患者，其中静脉血栓栓塞症(Venous Thromboembolism, VTE)患者26例；其他患者339例，包括慢性阻塞性肺疾病，间质性肺病，支气管扩张，支气管哮喘，社区获得性肺炎，肺癌以及肺结核。VTE组中血浆D-二聚体水平(1800.3 &#177; 1686.8 ng/ml)显著高于非VTE组中血浆D-二聚体水平(1050.3 &#177; 1425.4 ng/ml) (p = 0.001)，但血浆D-二聚体水平在VTE与结核和肺癌无差异。无论是结核、肿瘤，还是社区获得性肺炎，伴有胸腔积液的患者血浆D-二聚体水平比不伴有胸腔积液的患者显著升高。用来鉴别结核性胸腔积液(TPE)和恶性胸腔积液(MPE)的血浆D-二聚体水平曲线下面积为0.796 (95%置信区间：0.571~0.968)。临界值为1720 ng/ml，灵敏度为69.2%，特异性为83.3%。结论：血浆D-二聚体水平升高对于鉴别VTE与其他非血栓性呼吸系统疾病的价值有限，尤其是结核和肿瘤。而血浆D-二聚体水平在TPE明显升高，其水平显著超过MPE，血浆D-二聚体水平可能作为鉴别TPE和MPE的一个辅助指标。</p></sec><sec id="s2"><title>关键词</title><p>D-二聚体，肺结核，肺癌，胸腔积液，诊断</p></sec><sec id="s3"><title>On Admission Plasma Levels of D-Dimer in Patients with Pulmonary Diseases Free from Thromboembolic Clinical Conditions</title><p>Zhiqiang Wang<sup>1</sup>, Zhenhui Liu<sup>1</sup>, Ai Cui<sup>2*</sup></p><p><sup>1</sup>Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing</p><p><img src="//html.hanspub.org/file/43-1571836x5_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/43-1571836x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Background and Objectives: The use of D-dimer testing improved the diagnostics in pulmonary embolism and venous thrombosis (VTE). The aim of the present study was to evaluate and compare the serum D-dimer levels in patients with various lung diseases and determine whether serum D-dimer could be helpful in predicting the etiology of those pulmonary diseases. Patients and Methods: The study group included 365 consecutive patients. There were 26 with acute VTE, 339 with COPD, interstitial lung diseases (ILDs), bronchiectasis, asthma, community-acquired pneumonia (CAP), lung malignancy and tuberculosis (TB). Plasma D-dimer levels were analyzed by using an ELISA-method on the day of admission. Results: Mean plasma D-dimer concentration was 1800.3 &#177; 1686.8 ng/ml in VTE and 1050.3 &#177; 1425.4 ng/ml in the non-VTE group (p = 0.001), especially in lung cancer, CAP, ILDs and TB. There was a significant elevated level of D-dimer in patients with pleural effusion (2085.7 &#177; 1707.4 ng/ml) compared with each diseases without pleural effusion (1041.1 &#177; 1230.8 ng/ml) (p &lt; 0.01). The area under curve when plasma D-dimer was used to differentiate TPE from MPE was 0.796 (95% confidence interval: 0.571~0.968). With a cut-off value of 1720 ng/ml, the sensitivity was 69.2% and the specificity was 83.3%. Conclusions: Plasma D-dimer levels are as higher as VTE in many lung diseases including lung cancer, CAP, ILDs and TB, especially in those diseases with pleural effusion. TPE has extremely elevated plasma D-dimer level and it may serve as a differential diagnostic marker for TPE from MPE.</p><p>Keywords:D-Dimer, Tuberculosis, Lung Cancer, Pleural Effusion, Diagnosis</p><disp-formula id="hanspub.40012-formula28"><graphic xlink:href="//html.hanspub.org/file/43-1571836x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/43-1571836x8_hanspub.png" /> <img src="//html.hanspub.org/file/43-1571836x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>D-二聚体是纤维蛋白的特异降解产物，其浓度增高与体内各种原因引起的血栓性疾病高度相关，同时也说明了纤溶活性增强。D-二聚体检测对于静脉血栓栓塞症(Venous thromboembolism, VTE)的诊断具有极为重要的意义 [<xref ref-type="bibr" rid="hanspub.40012-ref1">1</xref>]，但是，在许多非血栓形成疾病中，血浆D-二聚体水平也会明显升高，某些情况下诸如妊娠、充血性心力衰竭、肝脏疾病、肾病综合征及肾功能衰竭等。</p><p>血浆D-二聚体水平升高同样见于多种呼吸系统疾病，如：社区获得性肺炎(Community acquired pneumonia, CAP) [<xref ref-type="bibr" rid="hanspub.40012-ref2">2</xref>]，结核性胸腔积液 [<xref ref-type="bibr" rid="hanspub.40012-ref3">3</xref>]，慢性阻塞性肺疾病(Chronic obstructive pulmonary disease, COPD) [<xref ref-type="bibr" rid="hanspub.40012-ref4">4</xref>] 以及肺癌 [<xref ref-type="bibr" rid="hanspub.40012-ref5">5</xref>] 等。D-二聚体水平正常基本可排除VTE的诊断，但其升高在鉴别VTE与其他呼吸系统疾病的意义有限。但是，血浆D-二聚体水平在不同呼吸系统非血栓性疾病的表达水平并不清楚。</p><p>本研究的目的是通过比较VTE与不同非血栓性呼吸系统疾病的血浆D-二聚体水平，评价其在相应疾病与VTE相鉴别及在不同呼吸系统疾病诊断中的应用价值。</p></sec><sec id="s6"><title>2. 研究对象和方法</title><p>2019年4月至6月研究期间共连续收治了484名肺病患者。我们排除了接受抗凝治疗或有肺外肿瘤，缺血性神经疾病、缺血性心脏病、外周动脉疾病、充血性心力衰竭、严重肝肾疾病、炎症性肠病、慢性血栓栓塞性肺动脉高压，弥漫性血管内凝血，妊娠以及急性出血的患者，同时排除诊断不清的患者。26例急性VTE患者作为阳性对照组(图1)。</p><p>图1. 实验设计</p><p>本研究共包括365名患者，其中339名非VTE患者的诊断包括COPD急性加重(87例，25.7%)；间质性肺疾病(Interstitial lung disease, ILD) (59例，17.4%)；支气管扩张(26例，7.7%)；哮喘(29例，8.6%)；67例CAP (19.8%)，其中伴有胸腔积液的患者13例；50例肺癌患者(14.7%)，其中伴有恶性胸腔积液(Malignance pleural effusion, MPE) 12例；9例患者(6.2%)合并急性肺结核(Tuberculosis, TB)，结核性胸腔积液患者12例(Tuberculous pleural effusion, TPE) (如图1所示)。26例急性VTE患者作为阳性对照组，VTE的诊断主要依据为CT肺血管造影、肺通气灌注扫描以及超声检查。患者年龄为62.2 &#177; 16.0岁，男女比例为1:55。</p><p>D-二聚体测定法：</p><p>常规的实验室检查在入院当天进行。血浆D-二聚体水平采用酶联免疫吸附试验(ELISA) (VIDAS&#174;D-Dimer Exclusion™, BioM&#233;rieux SA, 法国)。D-二聚体的正常值为500 ng/ml。</p></sec><sec id="s7"><title>3. 统计学分析</title><p>采用SPSS17.0统计学软件，结果用均数 &#177; 标准差(x &#177; s)表示，应用t检验，p &lt; 0.05为有统计学差异。通过Wilcoxon检验对自变量进行数据分析，并且用受试者工作特征曲线(ROC)评估D-二聚体区分TPE和MPE的临界值。诊断临界值为特异性和灵敏度的最大值。</p></sec><sec id="s8"><title>4. 结果</title><p>1) VTE组患者的血浆D-二聚体水平显著高于非血栓组患者</p><p>VTE组与非血栓组患者的血浆D-二聚体水平均高于正常上限，VTE组患者血浆D-二聚体水平(1800.3 &#177; 1686.8 ng/ml)明显高于非血栓组患者血浆D-二聚体水平(1050.3 &#177; 1425.4 ng/ml) (p = 0.001) (如图2所示)。男性患者(1017.9 &#177; 1285.0 ng/ml)与女性患者(1237.2 &#177; 1688.3 ng/ml)的血浆D-二聚体水平无显著性差异(如图3所示)。</p><p>2) 不同的非血栓呼吸系统疾病患者血浆D-二聚体水平比较</p><p>非血栓性呼吸系统疾病患者血浆D-二聚体水平均高于相应参考值(如表1所示)。其中肺癌，社区获得性肺炎，间质性肺病以及肺结核患者血浆D-二聚体升高水平与VTE患者无明显差异。慢性阻塞性肺疾病、支气管哮喘和支气管扩张患者血浆D-二聚体升高水平有限，与VTE患者具有显著差异(如图4所示)。</p><p>图2. 非VTE患者与VTE患者血浆D-二聚体水平对照(Mean &#177; SD)</p><p>图3. 不同性别的血浆D-二聚体水平</p><p>图4. 不同肺部疾病的血浆D-二聚体水平(Mean &#177; SD)</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Plasma D-dimer concentration of different lung disease</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Mean &#177; SD (ng/ml)</th><th align="center" valign="middle" >p (与VTE相比)</th></tr></thead><tr><td align="center" valign="middle" >慢性阻塞性肺病</td><td align="center" valign="middle" >854.2 &#177; 1362.0</td><td align="center" valign="middle" >0.0197</td></tr><tr><td align="center" valign="middle" >肺癌</td><td align="center" valign="middle" >1052.7 &#177; 1300.5</td><td align="center" valign="middle" >0.1009</td></tr><tr><td align="center" valign="middle" >社区获得性肺炎</td><td align="center" valign="middle" >1372.58 &#177; 1495.1</td><td align="center" valign="middle" >0.5137</td></tr><tr><td align="center" valign="middle" >间质性肺疾病</td><td align="center" valign="middle" >1031.7 &#177; 1619.6</td><td align="center" valign="middle" >0.1269</td></tr><tr><td align="center" valign="middle" >肺结核</td><td align="center" valign="middle" >1806.8 &#177; 1511.9</td><td align="center" valign="middle" >0.6394</td></tr><tr><td align="center" valign="middle" >哮喘</td><td align="center" valign="middle" >641.3 &#177; 1322.4</td><td align="center" valign="middle" >0.0132</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >支气管扩张</th><th align="center" valign="middle" >763.8 &#177; 912.8</th><th align="center" valign="middle" >0.0146</th></tr></thead><tr><td align="center" valign="middle" >静脉血栓栓塞症</td><td align="center" valign="middle" >1800.3 &#177; 1686.8</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 不同肺部疾病的血浆D-二聚体浓度(Mean &#177; SD)</p><p>CTEPH = 慢性血栓栓塞性肺动脉高压；COPD = 慢性阻塞性肺疾病；CAP = 社区获得性肺炎；ILDs = 间质性肺病；VTE = 静脉血栓栓塞症。</p><p>3) 伴有与不伴有胸腔积液患者的血浆D-二聚体水平比较</p><p>将肺炎、肺结核和肺癌患者按照是否伴有胸腔积液分为胸腔积液组和无胸腔积液组。伴有胸腔积液的患者血浆D-二聚体水平(2085.7 &#177; 1707.4ng/ml)相比于无胸腔积液患者(1041.1 &#177; 1230.8 ng/ml)，出现了显著性升高(p &lt; 0.01) (如表2所示)，其中TPE患者的血浆D-二聚体水平甚至明显高于VTE患者(如图5所示)。</p><p>图5. 胸腔积液对肺炎，肺癌以及肺结核患者血浆D-二聚体水平的影响(Mean &#177; SD)</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The presence or absence of pleural effusion affects the levels of plasma D-dimer in patients with pneumonia, lung cancer and tuberculosis (Mean &#177; SD</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Mean &#177; SD (ng/ml)</th><th align="center" valign="middle" >p</th><th align="center" valign="middle" >p (与VTE相比)</th></tr></thead><tr><td align="center" valign="middle" >肺癌</td><td align="center" valign="middle" >873.9 &#177; 947.0</td><td align="center" valign="middle"  rowspan="2"  >0.097</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肺癌伴有胸腔积液</td><td align="center" valign="middle" >1618.9 &#177; 2014.3</td><td align="center" valign="middle" >0.9679</td></tr><tr><td align="center" valign="middle" >社区获得性肺炎</td><td align="center" valign="middle" >1142.7 &#177; 1268.1</td><td align="center" valign="middle"  rowspan="2"  >0.032</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CAP伴有胸腔积液</td><td align="center" valign="middle" >2226.4 &#177; 1967.4</td><td align="center" valign="middle" >0.5711</td></tr><tr><td align="center" valign="middle" >肺结核</td><td align="center" valign="middle" >509.9 &#177; 513.9</td><td align="center" valign="middle"  rowspan="2"  >0.001</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肺结核伴有胸腔积液</td><td align="center" valign="middle" >2604.9 &#177; 1358.0</td><td align="center" valign="middle" >0.0286</td></tr><tr><td align="center" valign="middle" >静脉血栓栓塞症</td><td align="center" valign="middle" >1800.3 &#177; 1686.8</td><td align="center" valign="middle" >--</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 胸腔积液的存在与否对肺炎，肺癌以及肺结核患者血浆D-二聚体的水平(Mean &#177; SD)</p><p>CAP = 社区获得性肺炎；VTE = 静脉血栓栓塞症。</p><p>4) 不同病因的胸腔积液患者的血浆D-二聚体水平比较</p><p>血浆D-二聚体的曲线下面积作为区别TPE和MPE的鉴别诊断指标。临界值为1720 ng/ml，灵敏度为69.2%，特异性为83.3%。AUC值为0.796 (95%置信区间：0.571~968) (如图6所示)。</p><p>图6. 血浆D-二聚体的曲线下面积作为区别TPE和MPE的鉴别诊断指标</p></sec><sec id="s9"><title>5. 讨论</title><p>本研究表明，肺病患者体内不论是否存在静脉栓塞，血浆D-二聚体水平均有可能升高。仅通过单一的D-二聚体浓度升高难以将VTE与其他肺病区分开，特别是肺癌，社区获得性肺炎，间质性肺病以及肺结核。伴有胸腔积液的患者血浆D-二聚体浓度明显高于无胸腔积液的患者。对于胸腔积液患者，在鉴别TPE和MPE时，血浆D-二聚体水平可作为参考，当其检测指标超过1720 ng/ml更倾向于诊断TPE。</p><p>研究发现血浆D-二聚体水平会在几种肺部疾病中升高，数值的升高反映了凝血和纤维蛋白溶解系统的激活。当前对于呼吸道疾病中D-二聚体水平的研究大多数都集中在COPD患者身上，研究发现合并肺栓塞的COPD急性加重期患者和不合并肺栓塞的COPD急性加重期患者的D-二聚体水平均升高了77% [<xref ref-type="bibr" rid="hanspub.40012-ref6">6</xref>]。凝血通路的激活可能伴随着肺功能下降。COPD患者血清CRP与D-二聚体呈正相关，与肺功能呈反相关，该病显著表现出全身炎症反应 [<xref ref-type="bibr" rid="hanspub.40012-ref7">7</xref>]，但是缺氧对D-二聚体的升高无影响 [<xref ref-type="bibr" rid="hanspub.40012-ref8">8</xref>]。</p><p>当凝血和纤维蛋白溶解指数开始变化(小鼠模型2周)时，在早期预防性使用低分子量肝素对缓解血栓前状态，缓解缺氧和改善COPD患者预后具有临床意义 [<xref ref-type="bibr" rid="hanspub.40012-ref9">9</xref>]。稳定期COPD的D-二聚体值与对照组相比无差别。本研究发现D-二聚体水平不仅在COPD中升高，而且在哮喘和支气管扩张中也会升高，但其升高程度远低于VTE患者。</p><p>特发性肺纤维化(IPF)患者(主要是IPF急性加重期患者)的D-二聚体水平显著升高 [<xref ref-type="bibr" rid="hanspub.40012-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40012-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40012-ref12">12</xref>]。研究认为血浆D-二聚体水平与IPF急性加重期患者的死亡率相关，所以抗凝治疗对IPF患者的生存有益 [<xref ref-type="bibr" rid="hanspub.40012-ref13">13</xref>]，但对于该结果仍存有争议。损伤后的组织修复过程中会产生炎症反应。已经证明炎症细胞因子在凝血和纤维蛋白溶解系统中起重要作用，该过程又会反过来影响炎症进程。血浆D-二聚体可作为炎症标志物，并且在ILD中具有预后价值 [<xref ref-type="bibr" rid="hanspub.40012-ref12">12</xref>]。血浆D-二聚体水平升高与CAP和肺癌的病情严重程度和死亡率相关 [<xref ref-type="bibr" rid="hanspub.40012-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40012-ref15">15</xref>]。我们发现ILD，CAP，肺癌和VTE之间的D-二聚体水平无显著性差异。</p><p>炎症与凝血的关系对胸腔积液的病理生理发展至关重要。组织损伤后，凝血酶开始直接作用于纤维蛋白原，并产生纤维蛋白。为了维持生理平衡，抗凝血酶附着于新形成的纤维蛋白上并阻断凝血酶的活性。体内纤维蛋白的形成受纤维蛋白溶解系统控制。一旦形成纤维蛋白，就会伴随继发性纤维蛋白溶解系统的激活，并且将观察到D-二聚体水平的升高。研究发现结核性胸腔积液的D-二聚体水平比其他类型的胸腔积液水平高 [<xref ref-type="bibr" rid="hanspub.40012-ref16">16</xref>]，本研究的对照组不仅包括恶性胸腔积液和旁肺炎胸腔积液，还包括心力衰竭引起的胸腔积液，它们可能都是渗出液，所以其D-二聚体比对照组的平均水平低很多。我们的研究发现血浆D-二聚体在渗出液中显著升高，尤其是在TPE中。D-二聚体水平升高 &gt; 1720 ng/ml可能有助于TPE的诊断，但对MPE的诊断无帮助。</p><p>我们的研究尚存不足之处。首先，本研究是观察性研究，我们没有探讨关于凝血和纤维蛋白溶解系统的其他数据。其次，我们没有进一步研究关于这些疾病是如何影响纤维蛋白溶解系统的具体机制。我们需进一步研究具体的机制来验证我们的发现。</p></sec><sec id="s10"><title>6. 结论</title><p>总之，在这项研究中，我们发现大多数肺病住院患者的血浆D-二聚体水平升高，尤其是在CAP，肺癌，ILD和TB中。与非胸腔积液患者相比，CAP和TB患者血浆D-二聚体升高程度显著增加。血浆D-二聚体可作为TPE区别于MPE的鉴别诊断指标。</p></sec><sec id="s11"><title>文章引用</title><p>王志强,刘珍慧,崔 瑷. 呼吸科非血栓住院患者血浆D-二聚体水平分析On Admission Plasma Levels of D-Dimer in Patients with Pulmonary Diseases Free from Thromboembolic Clinical Conditions[J]. 临床医学进展, 2021, 11(01): 293-301. https://doi.org/10.12677/ACM.2021.111043</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40012-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galie, N., Pruszczyk, P., et al. (2008) Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). European Heart Journal, 29, 2276-2315.</mixed-citation></ref><ref id="hanspub.40012-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Dominic, S., Margreet, S., Marianne, S., Bartels, P.C., van derWerf, T.S. and Boersma, W.G. (2012) D-Dimer Levels in Assessing Severity and Clinical Outcome in Patients with Community-Acquired Pneumonia. A Secondary Analysis of a Randomised Clinical Trial. European Journal of Internal Medicine, 23, 436-441.  
&lt;br&gt;https://doi.org/10.1016/j.ejim.2011.10.019</mixed-citation></ref><ref id="hanspub.40012-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Shen, Y., Yang, T., Jia, L., Wang, T., Chen, L., Wan, C., et al. (2013) A Potential Role for D-Dimer in the Diagnosis of Tuberculous Pleural Effusion. European Review for Medical and Pharmacological Sciences, 17, 201-205.</mixed-citation></ref><ref id="hanspub.40012-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Sabit, R., Thomas, P., Shale, D.J., Collins, P. and Linnane, S.J. (2010) The Effects of Hypoxia on Markers of Coagulation and Systemic Inflammation in Patients with COPD. Chest, 138, 47-51. &lt;br&gt;https://doi.org/10.1378/chest.09-2764</mixed-citation></ref><ref id="hanspub.40012-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kucher, N., Kohler, H.P., Dornhoefer, T., Wallmann, D. and Laemmle, B. (2003) Accuracy of D-Dimer/Fibrinogen Ratio to Predict Pulmonary Embolism: A Prospective Diagnostic Study. Journal of Thrombosis and Haemostasis, 1, 708-713. &lt;br&gt;https://doi.org/10.1046/j.1538-7836.2003.00145.x</mixed-citation></ref><ref id="hanspub.40012-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rutschmann, O.T., Cornuz, J., Poletti, P.-A., Bridevaux, P.-O., Hugli, O.W., Qanadli, S.D., et al. (2007) Should Pulmonary Embolism Be Suspected in Exacerbation of Chronic Obstructive Pulmonary Disease? Thorax, 62, 121-125.  
&lt;br&gt;https://doi.org/10.1136/thx.2006.065557</mixed-citation></ref><ref id="hanspub.40012-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Fogarty, A.W., Lewis, S.A., McKeever, T.M., Lowe, G.D.O., Clark, L. and Britton, J. (2010) The Association between Blood Coagulation Activity and Lung Function: A Population-Based Study. PLoS ONE, 5, e15014.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0015014</mixed-citation></ref><ref id="hanspub.40012-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sabit, R., Thomas, P., Shale, D.J., Collins, P. and Linnane, S.J. (2010) The Effects of Hypoxia on Markers of Coagulation and Systemic Inflammation in Patients with COPD. Chest, 138, 47-51. &lt;br&gt;https://doi.org/10.1378/chest.09-2764</mixed-citation></ref><ref id="hanspub.40012-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y.Q., Sun, N.N., Chen, Z.Z. and Tong, L. (2014) Optimal Time to Use Low Molecular Weight Heparin on Prethrombotic State of Rat Chronic Obstructive Pulmonary Disease Model. Chinese Medical Journal, 127, 518-521.</mixed-citation></ref><ref id="hanspub.40012-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Silva, D.R., Coelho, A.C., Gazzana, M.B., et al. (2012) D-Dimer Levels in Stable COPD Patients: A Case-Control Study. COPD, 9, 426-431. &lt;br&gt;https://doi.org/10.3109/15412555.2012.683840</mixed-citation></ref><ref id="hanspub.40012-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Bargagli, E., Madioni, C., Bianchi, N., Refini, R.M., Cappelli, R. and Rottoli, P. (2014) Serum Analysis of Coagulation Factors in IPF and NSIP. Inflammation, 37, 10-16. &lt;br&gt;https://doi.org/10.1007/s10753-013-9706-z</mixed-citation></ref><ref id="hanspub.40012-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Andersen, C.U., Mellemkjar, S., Nielsen-Kudsk, J.E., Bendstrup, E., Simonsen, U. and Hilberg, O. (2012) Diagnostic and Prognostic Role of Biomarkers for Pulmonary Hypertension in Interstitial Lung Disease. Respiratory Medicine, 106, 1749-1755. &lt;br&gt;https://doi.org/10.1016/j.rmed.2012.09.003</mixed-citation></ref><ref id="hanspub.40012-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Noth, I., Anstrom, K.J., Calvert, S.B., de Andrade, J., Flaherty, K.R., Glazer, C., et al. (2012) A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 186, 88-95. &lt;br&gt;https://doi.org/10.1164/rccm.201202-0314OC</mixed-citation></ref><ref id="hanspub.40012-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Snijders, D., Schoorl, M., Schoorl, M., Bartels, P.C., van derWerf, T.S. and Boersma, W.G. (2012) D-Dimer Levels in Assessing Severity and Clinical Outcome in Patients with Community-Acquired Pneumonia. A Secondary Analysis of a Randomized Clinical Trial. European Journal of Internal Medicine, 23, 436-441.  
&lt;br&gt;https://doi.org/10.1016/j.ejim.2011.10.019</mixed-citation></ref><ref id="hanspub.40012-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Y.-X., Yang, Z.-M., Feng, J., Shan, Y.-J., Wang, W.-L. and Mei, Y.-Q. (2013) High Plasma D-Dimer Level Is Associated with Decreased Survival in Patients with Lung Cancer: A Meta-Analysis. Tumor Biology, 34, 3701-3704.  
&lt;br&gt;https://doi.org/10.1007/s13277-013-0953-2</mixed-citation></ref><ref id="hanspub.40012-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Shen, Y., Yang, T., Jia, L., Wang, T., Chen, L., Wan, C., et al. (2013) A Potential Role for D-Dimer in the Diagnosis of Tuberculous Pleural Effusion. European Review for Medical and Pharmacological Sciences, 17, 201-205.</mixed-citation></ref></ref-list></back></article>